Telephone
61.2.8315.7003
Address
Level 33 264 George Street Australia Square Sydney, New South Wales (NSW) 2000
Description
Immutep Ltd. is a clinical stage biotechnology company, which engages in the development of LAG-3 related immunotherapeutic products for cancer and autoimmune diseases. Its products include eftilagimod alpha (IMP321), IMP761, leramilimab (IMP701), and GSK‘781 (IMP731). The company was founded on May 21, 1987, and is headquartered in Sydney, Australia.
Market Cap
PE
EV/EBITDA
DIV Yield
Franking
Ex Dividend Date (est.)
52 weeks range
Low 0.22 - 0.41
Trade Value (12mth)
AU$90,774.00
1 week
6.9%
1 month
3.33%
YTD
14.5%
1 year
-12.53%
All time high
4.10679
EPS 3 yr Growth
33.000%
EBITDA Margin
N/A
Operating Cashflow
-$35m
Free Cash Flow Return
-30.30%
ROIC
-34.20%
Interest Coverage
-2,101.60
Quick Ratio
13.80
Shares on Issue (Fully Dilluted)
913m
HALO Sector
Healthcare
Next Company Report Date
28-Aug-24
Ex Dividend Date (est.)
N/A
Next Dividend Pay Date (est.)
N/A
Reporting Currency
AUD
Short Sell (% of issue)
0.38
Date | Announcements |
---|---|
31 October 23 |
Immutep Quarterly Activities Report and Appendix 4C
×
Immutep Quarterly Activities Report and Appendix 4C |
31 October 22 |
Change of Registry Address
×
Change of Registry Address |
31 October 13 |
Prima BioMed Limited - Annual Report on Form 20-F filed with SEC (PRR-AU)
×
Prima BioMed Limited - Annual Report on Form 20-F filed with SEC (PRR-AU) |
31 May 23 |
Trading Halt
×
Trading Halt |
31 May 23 |
A$80 million fully underwritten equity raising
×
A$80 million fully underwritten equity raising |
31 May 23 |
Immutep Capital Raising Presentation
×
Immutep Capital Raising Presentation |
31 May 23 |
Proposed issue of securities - IMM
×
Proposed issue of securities - IMM |
31 May 23 |
Cleansing Notice
×
Cleansing Notice |
31 March 23 |
Change in substantial holding
×
Change in substantial holding |
31 March 23 |
Positive Final Data in 2nd Line Metastatic NSCLC Patients
×
Positive Final Data in 2nd Line Metastatic NSCLC Patients |
31 July 23 |
Immutep Quarterly Activities Report and Appendix 4C
×
Immutep Quarterly Activities Report and Appendix 4C |
31 July 23 |
Efti clinical data to be presented at ESMO Congress 2023
×
Efti clinical data to be presented at ESMO Congress 2023 |
31 July 15 |
Prima BioMed Limited - 2015 EGM CEO's Presentation (PRR-AU)
×
Prima BioMed Limited - 2015 EGM CEO's Presentation (PRR-AU) |
31 January 22 |
Immutep to present at February Investor Conferences
×
Immutep to present at February Investor Conferences |
31 January 14 |
Prima to present at Annual BIO CEO & Investor Conference (PRR-AU)
×
Prima to present at Annual BIO CEO & Investor Conference (PRR-AU) |
31 August 22 |
Appendix 4E & 2022 Full Year Statutory Accounts
×
Appendix 4E & 2022 Full Year Statutory Accounts |
30 September 22 |
Becoming a substantial holder from AEF
×
Becoming a substantial holder from AEF |
30 September 19 |
Annual Report to shareholders
×
Annual Report to shareholders |
30 September 19 |
Notice of Annual General Meeting/Proxy Form
×
Notice of Annual General Meeting/Proxy Form |
30 September 19 |
Immutep Investor Presentation
×
Immutep Investor Presentation |
30 September 11 |
Prima BioMed Limited - Notice of Annual General Meeting/Proxy Form (PRR-AU)
×
Prima BioMed Limited - Notice of Annual General Meeting/Proxy Form (PRR-AU) |
30 September 11 |
Prima BioMed Limited - Annual Report to shareholders (PRR-AU)
×
Prima BioMed Limited - Annual Report to shareholders (PRR-AU) |
30 October 18 |
AusBiotech Invest presentation slides
×
AusBiotech Invest presentation slides |
30 November 09 |
2009 AGM Presentation (PRR-AU)
×
2009 AGM Presentation (PRR-AU) |
30 November 09 |
Results of 2009 Annual General Meeting (PRR-AU)
×
Results of 2009 Annual General Meeting (PRR-AU) |
30 May 14 |
Prima BioMed Limited - Conference call to discuss CAN-003 data presented at ASCO (PRR-AU)
×
Prima BioMed Limited - Conference call to discuss CAN-003 data presented at ASCO (PRR-AU) |
30 March 23 |
Expansion of INSIGHT-003 trial for Efti in 1st Line NSCLC
×
Expansion of INSIGHT-003 trial for Efti in 1st Line NSCLC |
Load More
Load Less
Historical data
Forecasted data
Load More
Load Less
Historical data
Forecasted data
Load More
Load Less
Historical data
Forecasted data
Load More
Load Less
Percent of Issue
Value ($M)
Prior Change
7 Day Change
1 Month Change
3 Month Change
Access data on short interest, stock performance, and potential short-selling candidates across various markets to make informed decisions and optimize your trading strategies.
Unlock true investor intelligence
Research, trade and manage global markets from one place with HALO Global. It’s trading - the way you want it.
Get the latest insights and hot tips delivered right to your inbox
HALO Technologies Pty Ltd ABN 54 623 830 866 is a Corporate Authorised Representative No 1261916 of Macrovue Pty Ltd ABN 98 600 022 679 AFSL 484264. Macrovue Pty Ltd is a wholly owned subsidiary of HALO Technologies Pty Ltd.